Results from the TARGET-TP clinical trial: Utilising a biomarker-driven, risk-directed primary thromboprophylaxis strategy in ambulatory patients receiving anticancer therapy for the treatment of lung and gastrointestinal cancers
In this medfyle
Patients with lung and gastrointestinal cancers were stratified according to a thrombosis risk assessment model based on fibrinogen and D-dimer levels. Risk-directed administration of prophylactic enoxaparin reduced thromboembolism and mortality rates, without safety concerns, and this approach allowed identification of low-risk individuals who could avoid intervention.
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
About this Medfyle
©2024 Medfyle. All rights reserved.
Original article:
Alexander M, Harris S, Underhill C, Torres J, Sharma S, Lee N, Wong H, Eek R, Michael M, Tie J, Rogers J, Heriot AG, Ball D, MacManus M, Wolfe R, Solomon BJ, Burbury K. Risk-Directed Ambulatory Thromboprophylaxis in Lung and Gastrointestinal Cancers: The TARGET-TP Randomized Clinical Trial. JAMA Oncol. 2023 Nov 1;9(11):1536-1545. doi: 10.1001/jamaoncol.2023.3634. PMID: 37733336; PMCID: PMC10514890.
The summary content was prepared by Rhian Shurlock for Medfyle, and reviewed by Marianna Aita, MD.
The authors of the original article and the publisher were not involved in the creation of the summary.
